HUP9800784A2 - Angiosztatin-fragmensek, aggregált angiosztatin és alkalmazásuk - Google Patents
Angiosztatin-fragmensek, aggregált angiosztatin és alkalmazásukInfo
- Publication number
- HUP9800784A2 HUP9800784A2 HU9800784A HUP9800784A HUP9800784A2 HU P9800784 A2 HUP9800784 A2 HU P9800784A2 HU 9800784 A HU9800784 A HU 9800784A HU P9800784 A HUP9800784 A HU P9800784A HU P9800784 A2 HUP9800784 A2 HU P9800784A2
- Authority
- HU
- Hungary
- Prior art keywords
- angiostatin
- fragments
- dna sequences
- angiogenic
- aggregated
- Prior art date
Links
- 102000012936 Angiostatins Human genes 0.000 title abstract 16
- 108010079709 Angiostatins Proteins 0.000 title abstract 16
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 title abstract 13
- 239000012634 fragment Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 230000002491 angiogenic effect Effects 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 230000018109 developmental process Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003068 molecular probe Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940076376 protein agonist Drugs 0.000 abstract 1
- 229940076372 protein antagonist Drugs 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
- 230000007998 vessel formation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány tárgyát endőtélsejt-prőliferációt gátló, angiősztatinnaknevezett anyagők képezik, melyek reverzíbilis módőn képesekendőtélsejtek prőliferációjának gátlására. A találmány tárgyátközelebbről hűmán testfőlyadékőkból - példáűl vérből vagy vizeletből -izőlálható vagy rekőmbináns, enzimatikűs vagy kémiai eljárásőkkalszintetizálható angiősztatin-prőteinek képezik.A találmány tárgyát képezik tővábbá endőtélsejtprőliferáció gátlásáraszőlgáló eljárásők, angiősztatin-fragmensek vagy aggregáltangiősztatin alkalmazásával; angingén (érképződéssel járó) főlyamatőkközvetítésével létrejött betegségekben szenvedő emlősök kezeléséreszőlgáló eljárásőké angiősztatin-fragmenseket vagy aggregáltangiősztatint tartalmazó készítmények; angiősztatinfragmenseket kódőlóDNS-szekvenciákat tartalmazó készítmények; ilyen DNS-szekvenciákattartalmazó vektőrők; a fenti vektőrőkat tartalmazó sejtek;angiősztatin-fragmensek expresszálására szőlgáló eljárásők; valamintaggregált angiősztatin előállítására szőlgáló eljárásők.A találmány tárgyáhőz tartőznak ezen felül, angiősztatinmeghatárőzásra alkalmazható diagnősztikűs vizsgálati eljárásők ésreagenskészletek; angiősztatin lőkalizálására alkalmas hisztőkémiaireagenskészletek; angiősztatint kódőló DNS-szekvenciák; angiősztatin-biőszintézis követésére alkalmazható mőlekűláris próbák;angiősztatinra specifikűs ellenanyagők; angiősztatin-receptőrhőzkötődni képes prőtein-agőnisták és -antagőnisták kifejlesztése;antiangiősztatin receptőr-specifikűs ellenanyag agőnisták ésantagőnisták; valamint angiősztatin-prőteinekhez kapcsőlt citőtőxikűsvegyületek.A találmány szerinti megőldás alkalmas angiőgenezissel (érképződéssel)kapcsőlatős betegségek kialakűlásának gátlására és angiőgén főlyamatőkszabályőzására.ŕ
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/429,743 US5885795A (en) | 1994-04-26 | 1995-04-26 | Methods of expressing angiostatic protein |
| US08/605,598 US5861372A (en) | 1996-02-22 | 1996-02-22 | Aggregate angiostatin and method of use |
| US08/612,788 US5837682A (en) | 1996-03-08 | 1996-03-08 | Angiostatin fragments and method of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9800784A2 true HUP9800784A2 (hu) | 1998-07-28 |
| HUP9800784A3 HUP9800784A3 (en) | 2000-07-28 |
Family
ID=27411639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9800784A HUP9800784A3 (en) | 1995-04-26 | 1996-04-26 | Angiostatin fragments and aggregate angiostatin and methods of use |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0824546B1 (hu) |
| JP (2) | JP3787157B2 (hu) |
| CN (1) | CN1195375A (hu) |
| AT (1) | ATE368051T1 (hu) |
| AU (1) | AU709633B2 (hu) |
| BR (1) | BR9608326A (hu) |
| CA (1) | CA2219081C (hu) |
| CZ (1) | CZ334097A3 (hu) |
| DE (1) | DE69637179T2 (hu) |
| ES (1) | ES2292174T3 (hu) |
| HK (1) | HK1002457A1 (hu) |
| HU (1) | HUP9800784A3 (hu) |
| MX (1) | MX9708217A (hu) |
| NO (1) | NO974943L (hu) |
| NZ (1) | NZ307044A (hu) |
| PL (1) | PL323256A1 (hu) |
| WO (1) | WO1996035774A2 (hu) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945403A (en) * | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US6440729B1 (en) | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
| US6358735B1 (en) | 1995-06-30 | 2002-03-19 | University Of Kansas Medical Center | Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
| HUP9900979A3 (en) * | 1995-12-13 | 2001-10-29 | Children S Medical Ct Corp Bos | Endothelial cell proliferation inhibitor and method of use |
| US5801012A (en) | 1996-09-17 | 1998-09-01 | Northwestern University | Methods and compositions for generating angiostatin |
| EP1705248A1 (en) * | 1997-10-01 | 2006-09-27 | G.D. Searle LLC. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment |
| WO1999026480A1 (en) * | 1997-11-20 | 1999-06-03 | Genetix Pharmaceuticals, Inc. | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases |
| US6797488B1 (en) | 1997-12-08 | 2004-09-28 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins |
| CA2312287A1 (en) * | 1997-12-08 | 1999-06-17 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system |
| CA2263784A1 (en) * | 1998-03-23 | 1999-09-23 | Megabios Corporation | Dual-tagged proteins and their uses |
| EP1074264B1 (en) * | 1998-04-28 | 2008-09-17 | Toshikazu Nakamura | Neovascularization inhibitors |
| AU3959499A (en) | 1998-05-28 | 1999-12-13 | Korea Green Cross Corporation | Process of purifying angiogenesis inhibitors |
| JP2002518341A (ja) | 1998-06-15 | 2002-06-25 | アーチ・デヴェロップメント・コーポレイション | 放射線療法と抗血管形成因子の組み合わせ |
| US6201104B1 (en) * | 1998-12-04 | 2001-03-13 | Entremed, Inc. | Angiogenesis—inhibiting protein binding peptides and proteins and methods of use |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| AU2974300A (en) * | 1999-01-28 | 2000-08-18 | Children's Medical Center Corporation | Plasminogen kringle 4 region fragments and methods of use |
| US7157556B1 (en) | 1999-02-10 | 2007-01-02 | The Children's Medical Center Corporation | Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use |
| ATE360062T1 (de) * | 1999-02-10 | 2007-05-15 | Childrens Medical Center | Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren |
| UY26929A1 (es) * | 2000-09-29 | 2002-04-26 | Abbott Lab | Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis |
| EP1494699A4 (en) * | 2002-04-11 | 2009-07-22 | Childrens Medical Center | METHOD FOR INHIBITING VASCULAR HYPERPERMEABILITY |
| US20070031379A1 (en) * | 2004-01-09 | 2007-02-08 | Lee Kyu H | Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same |
| WO2005079835A1 (ja) * | 2004-02-24 | 2005-09-01 | Ttc Co., Ltd. | Ｂｌアンジオスタチンを含む制がん剤 |
| ITMI20041962A1 (it) * | 2004-10-15 | 2005-01-15 | Istituto Naz Per La Ricerca S | "peptide di angiostatina e suoi impieghio terapeutici" |
| CN101219219B (zh) * | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
| WO2010070746A1 (ja) * | 2008-12-17 | 2010-06-24 | 株式会社ティムス | イヌアンジオスタチン様ポリペプチド |
| JP5749229B2 (ja) * | 2012-07-31 | 2015-07-15 | 京セラドキュメントソリューションズ株式会社 | ジェスチャー管理プログラム及び情報処理装置 |
| CN106890324A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| DK3395354T3 (da) | 2015-12-18 | 2024-06-03 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af diabetisk nefropati |
| TWI642442B (zh) | 2016-12-15 | 2018-12-01 | 深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備降低胰高血糖素分泌的藥物上的用途 |
| AU2018326835A1 (en) * | 2017-08-31 | 2020-03-26 | National University Of Singapore | Angio-3 for treatment of retinal angiogenic diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885795A (en) * | 1994-04-26 | 1999-03-23 | The Children's Medical Center Corporation | Methods of expressing angiostatic protein |
-
1996
- 1996-04-26 AT AT96913208T patent/ATE368051T1/de active
- 1996-04-26 BR BR9608326-3A patent/BR9608326A/pt unknown
- 1996-04-26 CZ CZ973340A patent/CZ334097A3/cs unknown
- 1996-04-26 PL PL96323256A patent/PL323256A1/xx unknown
- 1996-04-26 JP JP53410496A patent/JP3787157B2/ja not_active Expired - Lifetime
- 1996-04-26 ES ES96913208T patent/ES2292174T3/es not_active Expired - Lifetime
- 1996-04-26 MX MX9708217A patent/MX9708217A/es unknown
- 1996-04-26 CA CA002219081A patent/CA2219081C/en not_active Expired - Lifetime
- 1996-04-26 NZ NZ307044A patent/NZ307044A/en not_active IP Right Cessation
- 1996-04-26 DE DE69637179T patent/DE69637179T2/de not_active Expired - Lifetime
- 1996-04-26 CN CN96194077A patent/CN1195375A/zh active Pending
- 1996-04-26 EP EP96913208A patent/EP0824546B1/en not_active Expired - Lifetime
- 1996-04-26 HU HU9800784A patent/HUP9800784A3/hu unknown
- 1996-04-26 WO PCT/US1996/005856 patent/WO1996035774A2/en active IP Right Grant
- 1996-04-26 AU AU55795/96A patent/AU709633B2/en not_active Expired
-
1997
- 1997-10-24 NO NO974943A patent/NO974943L/no not_active Application Discontinuation
-
1998
- 1998-02-25 HK HK98101446A patent/HK1002457A1/xx not_active IP Right Cessation
-
2000
- 2000-10-06 JP JP2000308481A patent/JP2001151691A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO974943L (no) | 1997-12-18 |
| DE69637179T2 (de) | 2008-04-10 |
| CZ334097A3 (cs) | 1998-04-15 |
| JPH11508228A (ja) | 1999-07-21 |
| JP3787157B2 (ja) | 2006-06-21 |
| EP0824546B1 (en) | 2007-07-25 |
| PL323256A1 (en) | 1998-03-16 |
| WO1996035774A3 (en) | 1997-02-13 |
| WO1996035774A2 (en) | 1996-11-14 |
| HUP9800784A3 (en) | 2000-07-28 |
| MX9708217A (es) | 1997-12-31 |
| CA2219081C (en) | 2004-02-24 |
| ATE368051T1 (de) | 2007-08-15 |
| NO974943D0 (no) | 1997-10-24 |
| EP0824546A2 (en) | 1998-02-25 |
| NZ307044A (en) | 2002-03-01 |
| AU5579596A (en) | 1996-11-29 |
| JP2001151691A (ja) | 2001-06-05 |
| CA2219081A1 (en) | 1996-11-14 |
| BR9608326A (pt) | 2000-03-08 |
| CN1195375A (zh) | 1998-10-07 |
| AU709633B2 (en) | 1999-09-02 |
| HK1002457A1 (en) | 1998-08-28 |
| DE69637179D1 (de) | 2007-09-06 |
| ES2292174T3 (es) | 2008-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9800784A2 (hu) | Angiosztatin-fragmensek, aggregált angiosztatin és alkalmazásuk | |
| RU2305133C2 (ru) | Ген новой сериновой протеазы, родственной dppiv | |
| Lin et al. | Immunochemical characterization of two isoforms of rat liver ecto-ATPase that show an immunological and structural identity with a glycoprotein cell-adhesion molecule with M r 105,000 | |
| JP2001218599A (ja) | Ｉｇｆ−１レセプターと相互作用するタンパク質、それをコードする遺伝子及びそれらの使用 | |
| CA2266325A1 (en) | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof | |
| KR20080102408A (ko) | 혈관 종양 마커 | |
| JP2001513886A (ja) | 前立腺ガンの免疫診断のための化合物およびそれらの使用方法 | |
| KR19990087802A (ko) | 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법 | |
| JP2006325596A (ja) | シアロアドヘシンファミリーメンバー−２（ｓａｆ−２） | |
| KR20210111761A (ko) | 단백질 기능 및 상호작용을 제어하기 위한 시약 및 방법 | |
| Chinni et al. | Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. | |
| CA2344590A1 (en) | Treatment of inflammatory disease | |
| Shin et al. | Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF | |
| KR20020007362A (ko) | 유방암의 면역요법 및 진단용 화합물 및 이의 사용 방법 | |
| US5846826A (en) | Isolated cytolytic T cell line specific to complexes of HLA-B44 molecules and specific nonapeptides | |
| JPH06505011A (ja) | ｅｒｂＢ−２受容体タンパク質に結合し且つ細胞性応答を誘導するリガンド成長因子 | |
| CN116322750A (zh) | 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 | |
| US6872558B1 (en) | Heparanase-2 a member of the heparanase protein family | |
| KR102525734B1 (ko) | 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법 | |
| Herley et al. | Characterization of the VEGF binding site on the Flt-1 receptor | |
| JP2002518016A5 (hu) | ||
| JP4190291B2 (ja) | 癌細胞の増殖を調節するのに有用なポリヌクレオチド | |
| WO2007052561A1 (ja) | Ｓｌｉｍ１とｕｓｐの相互作用阻害による心筋肥大の阻害方法および阻害剤 | |
| KR101227434B1 (ko) | 유방암 줄기세포 특이적 마커인 ｃｄ４４ 단백질 표적용 펩타이드 및 이의 이용 | |
| US6140483A (en) | Human polyhomeotic 2 (hph2) acts as a tumor suppressor |